A new publication involving pasireotide appeared on July 24, 2026. The paper, titled "Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors," was published in the journal Pituitary.
This is a new addition to the published literature referencing pasireotide, an approved compound. The publication record indicates the study examines drug sensitivity using patient-derived 3D cultures in the context of acromegaly, alongside associations with clinical predictors, as reflected in its title.
No results, conclusions, or efficacy data from this publication are included here. This brief reports only that the publication exists, its title, its journal, and its date, as provided in the source record. Readers interested in the specific findings, methodology, or clinical implications of the study should consult the original publication directly through the listed source.
For general background on pasireotide, including its approved regulatory status and other available information, readers can refer to the compound overview.